Stay updated on Safety Tolerance Efficacy in IPF Clinical Trial
Sign up to get notified when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.

Latest updates to the Safety Tolerance Efficacy in IPF Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference2%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has been updated to include new details about the administration of FG-3019 for Idiopathic Pulmonary Fibrosis, specifically regarding dosing and treatment duration for different cohorts. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference27%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
Stay in the know with updates to Safety Tolerance Efficacy in IPF Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Tolerance Efficacy in IPF Clinical Trial page.